je.st
news
Tag: arterial
Potential Arterial Countermeasures
2019-07-17 20:56:09| PortlandOnline
A table listing potential safety countermeasures for East Portland arterial streets, including crash modification factors PDF Document, 83kbCategory: Meeting 2
Tags: potential
arterial
countermeasures
East Portland Arterial Streets Strategy Opinion Survey
2019-06-24 19:56:14| PortlandOnline
Share your experiences and priorities for the arterial streets in the EPASS network
Tags: east
opinion
strategy
survey
East Portland Arterial Streets Strategy
2019-05-01 22:55:08| PortlandOnline
PDF Document, 4,041kbCategory: EPASS: East Portland Arterial Streets Strategy
Tags: east
strategy
streets
portland
East Portland Arterial Streets Multimodal Atlas
2019-04-12 00:17:43| PortlandOnline
Sidewalk, bike lane, and crossing spacing data PDF Document, 4,477kbCategory: Technical Advisory Committee
Tags: east
streets
portland
atlas
Two New Post-Hoc Analyses of TRA 2°P TIMI 50 Study Showed ZONTIVITY (vorapaxar) Added to Aspirin and/or Clopidogrel Reduced Acute Limb Ischemia and Peripheral Revascularizations, Respectively, in Certain Patients with Peripheral Arterial Disease
2015-03-05 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. These and other post-hoc subgroup analyses from TRA-2°P are being presented at the 2015 American College of Cardiology Scientific Sessions KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from two post-hoc analyses of the TRA 2°P TIMI 50 (Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events) trial of ZONTIVITY (vorapaxar), one of the largest secondary prevention studies of an antiplatelet medicine. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestors:Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
added
study
reduced